Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful hard but unsuccessfully to create an one-time therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be used is actually an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the last several shares of mine. My 1st CytoDyn article, “CytoDyn: What To Do When It’s Too Good In order to Be True?”, set out all of the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such an extremely promotional image in the Uptick Newswire job interview that I came away with a bad viewpoint of the business.

Irony of irony, my bad viewpoint of the business has grown steadily, however, the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy and avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this technology and also connected intellectual property coming from Progenics to CytoDyn, and also roughly twenty five million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) and also the very first brand new drug program endorsement ($5 million), as well as royalty payments of five percent of net sales upon commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and numerous indications, it’s this individual therapy as well as a “broad pipeline of indications” since it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially advantageous therapy in dozens of indications.

Its opening banner on its site (below) shows an active company with diverse interests albeit centered on leronlimab, several disease sorts, multiple presentations in addition to multiple publications.

Can all this be smoke and mirrors? That is a question I’ve been asking myself through the very start of the interest of mine in this business. Judging by the multiples of thousands of various comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this particular question.

CytoDyn is a traditional battleground, or possibly some may say cult stock. Its adherents are fiercely shielding of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *